Comparison of the survivor and non-survivor groups
A comparison of the survivor and non-survivor groups is presented in
Tables 1 and 2. The prevalence of chronic heart failure (CHF) and
history of malignancy was significantly higher in the non-survivor group
than in the survivor group (p = 0.033 and p < 0.001,
respectively). The mean GNRI score was significantly lower in the
non-survivor group than in the survivor group (p < 0.001),
with 72 (74.2%) patients identified as having severe nutrition risk
(GNRI <82). Serum BUN and albumin levels were significantly
lower and the A-DROP score was significantly higher in the non-survivor
group than in the survivor group (BUN: p = 0.039, albumin: p <
0.001, A-DROP: p < 0.001). ABPC/SBT was more frequently
administered as an initial treatment regimen in the survivor group than
in the non-survivor group (p = 0.044). The frequency of first-choice
PIPC/TAZ exhibited a trend to be lower in the survival group than in the
non-survival group (survivor vs. non-survivor: 8.2% vs. 14.4%), but
this did not reach significance (p = 0.056). The frequency of initial
antibiotic change was significantly higher in the non-survivor group
than in the survivor group (p < 0.001). No significant
between-group difference was observed in the isolation rate of specific
pathogens, including PDR pathogens (Table 2).